Share on StockTwits

Merck & Co. (NYSE:MRK) is scheduled to issue its Q114 quarterly earnings data on Tuesday, April 29th. Analysts expect the company to announce earnings of $0.79 per share and revenue of $10.44 billion for the quarter. Merck & Co. has set its FY14 guidance at $3.35-3.53 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Merck & Co. (NYSE:MRK) last announced its earnings results on Wednesday, February 5th. The company reported $0.88 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter last year, the company posted $0.83 earnings per share. Merck & Co.’s revenue was down 3.6% compared to the same quarter last year. On average, analysts expect Merck & Co. to post $3.44 EPS for the current fiscal year and $3.69 EPS for the next fiscal year.

Merck & Co. (NYSE:MRK) opened at 57.24 on Monday. Merck & Co. has a 52-week low of $44.60 and a 52-week high of $58.32. The stock’s 50-day moving average is $56.22 and its 200-day moving average is $51.81. The company has a market cap of $168.3 billion and a P/E ratio of 39.14. Merck & Co. also saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 32,443,294 shares, an increase of 13.0% from the March 31st total of 28,708,787 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 11,401,160 shares, the short-interest ratio is currently 2.8 days.

Several analysts have recently commented on the stock. Analysts at Bank of America reiterated a “buy” rating on shares of Merck & Co. in a research note on Thursday. They now have a $62.00 price target on the stock. On a related note, analysts at Jefferies Group raised their price target on shares of Merck & Co. to $61.00 in a research note on Monday, April 14th. They now have a “hold” rating on the stock. Finally, analysts at MKM Partners raised their price target on shares of Merck & Co. from $64.00 to $70.00 in a research note on Friday, April 11th. They now have a “buy” rating on the stock. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.